Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic lymphocytic leukemia
Pharma
Trial results show value of Lilly's Jaypirca in front-line CLL
By nailing the primary endpoint in a trial of Jaypirca, Eli Lilly has brought the drug closer to becoming available to a broader group of patients.
Kevin Dunleavy
Sep 8, 2025 11:37am
Lilly's BTK Jaypirca makes the grade versus Imbruvica
Jul 29, 2025 4:56pm
BeiGene's Brukinsa surpasses AZ’s Calquence in quarterly sales
Feb 27, 2025 10:56am
ASH: Lilly defends survival data blemish in novel BTK trial win
Dec 9, 2024 5:45pm
AbbVie CLL survey shows emotional impact on patients of color
Dec 9, 2024 11:48am
ASH: AstraZeneca proposes fixed-duration Calquence combos in CLL
Dec 8, 2024 11:00am
